NCT06636877已完成1 期
A Randomized, Open-label, Single Dose, Two-way Replicate Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- Area under the concentration-time curve from time zero to time τ
研究概览
简要总结
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-3" and "BR1019-2" in healthy volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Those have body mass index (BMI) within the range of 18.0 to 30.0kg/m2 at screening visit.
- •For men, Those who weigh 50 kg or more
- •For women, Those who weigh 45 kg or more
- •Those who spontaneously decide to participate and sign written consent to comply with the subject's precautions during the clinical trial period after listening to and fully understanding detailed explanation of this clinical trial
- •Those who agree to rule out the possibility of their and their spouses' or sexual partners' pregnancy by using methods of contraception accepted in clinical trial*(Except for hormone drugs) from the date of the first administration of the investigational products to 7 days after the last administration and disagrees to provide their sperm or ovum.
- •Methods of contraception accepted in clinical trial: Combined use of intrauterine device, vasectomy, tubal ligation, and barrier methods (male condom, female condom, cervical cap, contraceptive diaphragm, sponge, etc.) or combined use of two or more barrier methods if spermicide is used.
排除标准
- •Those who have taken drugs that induce and inhibit metabolizing enzymes such as barbiturate within 30 days prior to the first day of administration or have taken ETC, OTC, Oriental medicine, health functional food concerned about affecting this clinical trial within 10 days prior to the first day of administration. (however, participation is possible considering pharmacokinetic and pharmacodynamic properties such as Interaction of investigational products, half-life)
- •Those who have participated in bioequivalence tests or other clinical trials and administered their investigational products within 6 months prior to the first administration date. (However, the termination for participation in other clinical trials are based on the last administration date of their investigational products)
- •Those who have a medical history of gastrointestinal surgery (Except for simple appendectomy, hernia surgery) or gastrointestinal diseases that may affect the absorption of drugs.
- •In the case of a female subject, pregnant woman, those suspected pregnancy or lactating woman.
研究组 & 干预措施
BR1019
Experimental
干预措施: BR1019 (Drug)
BR1019-2 + BR1019-3
Active Comparator
干预措施: BR1019-2 (Drug)
BR1019-2 + BR1019-3
Active Comparator
干预措施: BR1019-3 (Drug)
结局指标
主要结局
Area under the concentration-time curve from time zero to time τ
时间窗: 0-48 hours after administration
Maximum concentration of drug in plasma
时间窗: 0-48 hours after administration
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"Essential HypertensionType 2 Diabetes MellitusNCT06226727Boryung Pharmaceutical Co., Ltd52
已完成
1 期
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed ConditionsEssential HypertensionNCT06744439Boryung Pharmaceutical Co., Ltd49
已完成
1 期
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed ConditionsEssential HypertensionNCT06744062Boryung Pharmaceutical Co., Ltd48
已完成
1 期
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy VolunteersHypertensionNCT06008015Boryung Pharmaceutical Co., Ltd44
Unknown
1 期
The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-375Type 2 Diabetes MellitusNCT03848637Chong Kun Dang Pharmaceutical28